TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29852037
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) at a dose of 54 Gy delivered in 3 fractions of 18 Gy over 1.5 to 2.0 weeks
Study: 29852933
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) in combination with optimal medical therapy (OMT)
Study: 29852973
Drug: Other glucose-lowering
Normalized name: Other blood glucose lowering drugs, excl. insulins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other glucose-lowering drugs (GLDs)
Study: 29853437
Drug: Weekly newsletter
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly newsletter for 5 months (Control)
Study: 29853657
Drug: Ziv-aflibercept and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziv-aflibercept and ganetespib combination treatment
Study: 29854429
Drug: Vitreomacular adhesion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitreomacular adhesion (VMA) resistant to pharmacotherapy
Study: 29854447
Drug: Cereal-based snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal-based snack bar with added plant stanol ester (1.6 g plant stanols/day)
Study: 29854928
Drug: ABT-126 25
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 25 mg once daily
Study: 29854928
Drug: ABT-126 5
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-126 5 mg once daily
Study: 29854933
Drug: 250-mg rilapladib
Normalized name: Rilapladib
DrugBank: Rilapladib (DB05119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-mg rilapladib once daily for 24 weeks
Study: 29854939
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day memantine plus 24 mg/day galantamine-CR
Study: 29854939
Drug: 24 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg/day galantamine-CR plus placebo
Study: 29855752
Drug: Pump infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pump infusion
Study: 29855752
Drug: Rapid push
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid push infusion
Study: 29855806
Drug: Panitumumab 9
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab 9 mg/Kg combined with oxaliplatin 130 mg/m2 and capecitabine (dosage not specified)
Study: 29856132
Drug: Active or
Normalized name: Factive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active or substituted drug consumption
Study: 29856132
Drug: Alcohol intake
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intake > 20 g/day or history of alcohol abuse
Study: 29856132
Drug: Age, gender,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, gender, country of birth, positive HCV serology, HIV-related factors (AIDS status, use of combination antiretroviral therapy (cART), nadir and current CD4 counts, HIV viral load)
Study: 29856824
Drug: Oral niclosamide
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral niclosamide 500mg TID
Study: 29856824
Drug: Oral niclosamide
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral niclosamide 1000mg TID
Study: 29856824
Drug: Oral niclosamide
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral niclosamide 1500mg TID
Study: 29856824
Drug: Enzalutamide (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (standard dose)
Study: 29856824
Drug: Oral niclosamide
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral niclosamide (overall)
Study: 29857090
Drug: Biologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapy (infliximab, adalimumab, certolizumab, natalizumab, ustekinumab)
Study: 29857090
Drug: Infants whose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants whose mothers received biologics, immunomodulators, or combination therapy
Study: 29858106
Drug: H.E.L.P.-apheresis (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: H.E.L.P.-apheresis (2-6 treatments)
Study: 29858465
Drug: Low mean
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low mean daily cadences
Study: 29859740
Drug: Sofosbuvir-velpatasvir-voxilaprevir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir-velpatasvir-voxilaprevir (400 mg sofosbuvir, 100 mg velpatasvir, 100 mg voxilaprevir once daily for 12 weeks)
Study: 29859909
Drug: Sufficient preconception
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient preconception 25-hydroxyvitamin D (≥75 nmol/L)
Study: 29859909
Drug: Insufficient preconception
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insufficient preconception 25-hydroxyvitamin D (<75 nmol/L)
Study: 31841594
Drug: Ivosidenib 500
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivosidenib 500 mg daily
Study: 29862269
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants
Study: 29862437
Drug: Fludarabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine and rituximab with escalating doses of lenalidomide
Study: 29862466
Drug: Piperacillin (extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (extended and continuous infusion)
Study: 29862466
Drug: Standard intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intermittent piperacillin dosing regimens
Study: 29863388
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg amitriptyline on four consecutive days
Study: 29863899
Drug: Optimal step-down
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal step-down therapy with moderate-dose combination inhaled corticosteroids/long-acting β-agonists
Study: 29864044
Drug: Topical dorzolamide-timolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide-timolol, administered as one drop twice daily for the duration of the study.
Study: 29866628
Drug: 75-g Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-g Oral Glucose Tolerance Test (OGTT) in PD patients
Study: 29867602
Drug: sequence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequence of treatments
Study: 29868792
Drug: Media suggestions,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Media suggestions, NHS vaccination leaflet, health care workers' suggestions, uncertainty-related beliefs, perceived sensitivity to medicines, pessimism, and anxiety
Study: 29869534
Drug: Subretinal injection
Normalized name: LUXTURNA Suspension for Subretinal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal injection of rAAV2-CB-hRPE65
Study: 29870382
Drug: ΔHgb <1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ΔHgb <1.0 g/dL
Study: 29870382
Drug: ΔHgb ≥1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ΔHgb ≥1.0 to <2.0 g/dL
Study: 29870382
Drug: ΔHgb ≥2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ΔHgb ≥2.0 to <3.0 g/dL
Study: 29870382
Drug: ΔHgb ≥3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ΔHgb ≥3.0 to <4.0 g/dL
Study: 29870382
Drug: ΔHgb ≥4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ΔHgb ≥4.0 g/dL
Study: 29872570
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) lymphodepletion prior to CAR T-cell therapy
Study: 29872570
Drug: CAR T-cell
Normalized name: CD123-CD33cCAR T-cells
DrugBank: ICG-136 (DB17343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR T-cell therapy alone
Study: 29874177
Drug: Functional significance
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional significance examination by patch-clamp electrophysiological recording
Study: 29875066
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for about 2 years or until disease progression, unacceptable toxicity, patient withdrawal, or investigator decision.
Study: 29875066
Drug: Pembrolizumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab treatment
Study: 29875084
Drug: Tablet-based decision
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based decision support tool
Study: 29877739
Drug: Long-term macrolide
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term macrolide therapy for refractory MAC-LD, median duration of treatment 32 months (interquartile range, 24-41 mo)
Study: 29877739
Drug: Mycobacterial genotyping
Normalized name: Mycobacterium phlei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterial genotyping of stored pre- and post-treatment isolates
Study: 29878058
Drug: Homeostasis model
Normalized name: CALCIUM HOMEOSTASIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeostasis model assessment of insulin resistance
Study: 29878653
Drug: Adeno-associated viral
Normalized name: Adeno-associated viral vector serotype 8 containing the human RPGR gene
DrugBank: Cotoretigene toliparvovec (DB16797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adeno-associated viral vectors (AAV) gene therapy
Study: 29878653
Drug: High vector
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High vector doses of AAV gene therapy
Study: 29878866
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for progressive midgut neuroendocrine tumors (specific intervention details not provided)
Study: 29879133
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning models using features from enrollment and level 1 treatment (up to week 2 response) of STAR*D
Study: 29879133
Drug: Early or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early or initial treatment response or symptom severity at week 2
Study: 29879283
Drug: Panitumumab plus
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab plus neoadjuvant chemotherapy (1 dose of panitumumab 2.5 mg/kg followed by 4 cycles of panitumumab 2.5 mg/kg, nab-paclitaxel 100 mg/m2, and carboplatin weekly, then 4 cycles of fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 every 3 weeks)
Study: 29879283
Drug: Panitumumab plus
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab plus neoadjuvant chemotherapy
Study: 29880009
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at Guanyuan (CV4), Sanyinjiao (SP6), Taichong (LR3), Zhaohai (KI6) and Qichong (ST30)
Study: 29880049
Drug: RiseTx web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: RiseTx web-based intervention with activity tracker (Jawbone), goal of increasing walking by 3000 daily steps over 12 weeks.
Study: 29880583
Drug: BRAF inhibitor
Normalized name: B-Raf serine-threonine kinase (BRAF) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRAF inhibitor treatment, specific dosage and duration not mentioned
Study: 29880583
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, specific treatment not mentioned
Study: 29881956
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine replacement therapy (NRT) 14 or 21 mg per day
Study: 29882017
Drug: Ibrutinib (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (560 mg, single dose) administered after an overnight fast on day 1
Study: 29882017
Drug: Ibrutinib (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (560 mg) administered with omeprazole (40 mg) on day 7
Study: 29882017
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg) administered alone on days 3-6, 1 hour before breakfast
Study: 29884204
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in CTCs during treatment
Study: 29884223
Drug: Biotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotherapy after first Anti-TNF treatment failure
Study: 29884223
Drug: First Anti-TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: First Anti-TNF treatment
Study: 29884695
Drug: PCV10 in
Normalized name: PCV10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV10 in a two-dose schedule
Study: 29884695
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving two doses of PCV10 at 18 and 24 months
Study: 29884695
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group of 200 children receiving one dose of PCV10 at 24 months
Study: 29885885
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) injection intravenously at the end of endometriosis resection.
Study: 29886024
Drug: Ivacaftor 50
Normalized name: ivacaftor 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivacaftor 50 mg or 75 mg orally every 12 hours for 3 days plus one morning (part A) or 24 weeks (part B)
Study: 29886024
Drug: Ivacaftor 50
Normalized name: ivacaftor 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivacaftor 50 mg orally every 12 hours for 24 weeks (part B)
Study: 29886154
Drug: Sofosbuvir/velpatasvir (SOF/VEL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir/velpatasvir (SOF/VEL) 400/100 mg daily for 12 weeks
Study: 29888205
Drug: Axitinib in
Normalized name: Product containing axitinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib in combination with best supportive care (BSC)
Study: 29888205
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with best supportive care (BSC)
Study: 29889751
Drug: Inpatient transcervical
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient transcervical catheter placement with concomitant oxytocin infusion
Study: 29890128
Drug: Mifepristone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone treatment for 3 months
Study: 29890892
Drug: Group sequential
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group sequential procedure based on the asymptotic covariance of the sequence of Wald statistics
Study: 29890892
Drug: Group sequential
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group sequential procedure based on the canonical joint distribution
Study: 29891853
Drug: Capsule sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule sponge (25 mm, 10 pores or 20 pores per inch) swallowed by patients.
Study: 29892208
Drug: Procarbazine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procarbazine and CCNU chemotherapy
Study: 29893797
Drug: AS03-adjuvanted H1N1pdm09
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H1N1pdm09 vaccine
Study: 29895073
Drug: G-POEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-POEM
Study: 29895178
Drug: Ad26.ZEBOV/MVA-BN-Filo prime-boost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV/MVA-BN-Filo prime-boost Ebola vaccine regimen
Study: 29895331
Drug: Noninvasive ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive ventilation (NIV) as first-line treatment
Study: 29896154
Drug: Levosulpiride (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride (75 mg/day orally TID) for 8 weeks (DME and NPDR), 1 week (PDR before vitrectomy), or 12 weeks (DME plus ranibizumab)
Study: 29896154
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose pill, orally TID)
Study: 29896154
Drug: Levosulpiride (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride (75 mg/day orally TID)
Study: 29897474
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity index (ISI)
Study: 29897474
Drug: Estimated 24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimated 24-hour insulin level
Study: 29898762
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tumor subtypes with tHb
Study: 29899062
Drug: Adoptive T-cell
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive T-cell transfer therapy (ACT) targeting MART1 antigen
Study: 29899212
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate (once daily for 4 days)
Study: 29899212
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of tedizolid phosphate and pseudoephedrine (60 mg on day 5)
Study: 29899212
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 4 days)
Study: 29899820
Drug: Chimeric antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor (CAR) targeting BCMA using a fully human single chain variable fragment (scFv)
Study: 29899820
Drug: Immunohistochemical analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical analysis of normal tissue expression using commercially available polyclonal antibodies
Study: 29900143
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (2700 mg/day EPA: DHA ratio=2)
Study: 29901700
Drug: High-SFA diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-SFA diet (≥22 g/d)
Study: 29901700
Drug: Low-SFA diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-SFA diet (<22 g/d)
Study: 29901727
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at day 0
Study: 29901727
Drug: Insulin at
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin at day 28
Study: 29902097
Drug: Iron chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron chelation therapy (ICT) using deferasirox
Study: 29902097
Drug: Iron chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron chelation therapy (ICT)
Study: 29902683
Drug: 14 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 week supervised exercise-aided nicotine replacement therapy (NRT) cessation program
Study: 29902988
Drug: Holmium-166 radioembolization
Normalized name: holmium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holmium-166 radioembolization after peptide receptor radionuclide therapy (PRRT)
Study: 29903707
Drug: Valproate at
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate at 60 mg/kg per day with R-CHOP
Study: 29903793
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) 50 mg subcutaneously once monthly
Study: 29903860
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human angiotensin-converting enzyme 2 (rhACE2) at doses of 0.2 or 0.4 mg·kg
Study: 29905808
Drug: darunavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir 400/100 mg q24h
Study: 29905808
Drug: darunavir/ritonavir 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir 800/100 mg q24h
Study: 29908967
Drug: Clopidogrel (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (with aspirin)
Study: 29909069
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg DSM265
Study: 29909069
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg DSM265
Study: 29909069
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg DSM265
Study: 29909069
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg DSM265
Study: 29910050
Drug: Aliskiren (direct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (direct renin inhibitor) for 6 months
Study: 29910193
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy (antiplatelet therapy or anticoagulation)
Study: 29911997
Drug: Passive infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Passive infusion of the broadly neutralizing antibody VRC01 during analytical treatment interruption (ATI)
Study: 29912343
Drug: 3.7 GBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.7 GBq radioactive iodine (RAI) therapy
Study: 29913339
Drug: Remifentanil (≥0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (≥0.15 µg/kg/min)
Study: 29914560
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy with CT scans
Study: 29914560
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of history of severe hemorrhage, dual antiplatelet therapy, headache or vomiting, and abnormal Glasgow coma scale score
Study: 29914796
Drug: Convection-enhanced delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convection-enhanced delivery of a radioimmunotherapy agent targeting B7-H3 antigen, single infusion of 9.25 to 148 MBq at a concentration of about 37 MBq/mL.
Study: 29914948
Drug: Amoxicillin treatment
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin treatment